Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067236 · ClinicalTrials.gov registry record · Phase 2
Study of Oral PG-116800 Following a Heart Attack
A Phase 2 study, sponsored by Procter and Gamble.
- Completed
- Registry status
- Phase 2
- Development phase
- 253
- Enrollment target
NCT00067236: Completed Phase 2 study, sponsored by Procter and Gamble.
NCT00067236 is a Phase 2 study that has completed, run by Procter and Gamble. The registered enrollment target is 253 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00067236, a Phase 2 study, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 253 participants
- Enrollment target
Study Summary
The main purpose of the study is to test whether a possible new drug (called PG-116800) can prevent some of the damage to heart muscle in patients who have had a heart attack. The study will also supply information regarding possible uses of this compound in cardiovascular disease.
Primary Outcome
Mean change of left ventricular end diastolic volume index (mL/m2) as evaluated via ventricular end-diastolic volume index augmentation 90 days post Myocardial Infarction (MI)
Interventions
- DRUG Placebo tablet
- DRUG PG-116800 (given as PG-530742)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 253 participants |
| Start Date | 2003-09 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
What the finished NCT00067236 record still lists
NCT00067236 is an interventional study that assigns participants to a tested intervention. The registered 253 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo tablet is the first listed.
NCT00067236 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00067236 about?
NCT00067236 is a clinical study titled "Study of Oral PG-116800 Following a Heart Attack". The main purpose of the study is to test whether a possible new drug (called PG-116800) can prevent some of the damage to heart muscle in patients who have had a heart attack. The study will also supply information regarding possible uses of this compound in cardiovascular disease.
What is the current status of trial NCT00067236?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 253 participants. The study started on 2003-09. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00067236?
The interventions under investigation include: Placebo tablet (DRUG), PG-116800 (given as PG-530742) (DRUG).
Who is sponsoring clinical trial NCT00067236?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00067236's enrollment target sits among peer trials
253 220th of 2000 higher than 1,781 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia